Comparison of the conventional impregnation method using ammonium heptamolydate with a simple route to silica-supported molybdenum(VI) materials.

International audienceSilica-supported molybdenum oxide materials have been prepared by using the ability of molybdenum oxoperoxo complexes to interact with the surface hydroxyl groups of the support, which after calcinations, have a highly dispersed MoOx/SiO2 structure, and lead to leach-resistant catalysts; with a polyoxo precursor, (NH4)6[Mo7O24].4H2O, there is a formation of MoO3 clusters and a weaker MoO3/SiO2 interaction

The LPCTrap facility: A novel transparent Paul trap for high-precision experiments

A trap system has been built to perform high-precision β-decay experiments. The system is coupled to the low-energy beam line of the SPIRAL source at GANIL. The continuous ion beam from SPIRAL with energies between 10 and 20 keV is slowed down by means of a buffer-gas-filled RFQ trap and ejected thereafter as short ion bunches into a novel transparent Paul trap. Two pulsed cavities located downstream from the RFQ reduce the energy of the ion bunch down to about a hundred eV for an efficient capture in the Paul trap. We describe here the complete system along with the first results obtained with stable $^{4}$He^+$,$^{35}$Cl^+$ and $^{36,40}$Ar^+$ions from the SPIRAL ECR source. An overall efficiency of 8.7(8)×10-4 is achieved for$^{4}$He^+$ ions under specific conditions

Linear radio frequency quadrupole for the cooling and bunching of radioactive ion beams

A linear radio frequency quadrupole has been built for the transport, cooling, and bunching of radioactive ions extracted from an ECR source. The device uses the buffer gas cooling technique and was designed such as to extend the technique for the cooling of very light ions using H2 as buffer gas. We describe here the technical specifications of the device and present results of the first tests concerning the cooling and bunching of stable ions

Effect of alirocumab on mortality after acute coronary syndromes : an analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined with achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402